What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July 2014 issue of the journal “EMBO” by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin-based Lifespan extension therapy: IL-17 increases life span via up-regulation of its target gene BubR1
From Research Findings to Therapeutic Opportunity:
This study suggests an interleukin-based life extension therapy. IL-17, by increasing the expression of its target gene, it may increase the expression of BuBR1. Thereby, it may: (1) delay diseases of aging; (2) slow down aging; and (3) prolong median life span. Thus, pharmacological formulations encompassing“IL-17 or its activators“ may be used to extend the lifespan of an individual.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org or http://newbioideas.com
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., Interleukin-based Lifespan extension therapy: IL-17 increases life span via up-regulation of its target gene BubR1, 7/November/2016, 10.34 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Amount: $300#
Undisclosed information: How IL-17 increases the expression of BubR1 and extends mammalian life-span
# Research cooperation
Results guaranteed if not refunded